Derakhshan Behrad 4
4 · Edgewise Therapeutics, Inc. · Filed Aug 14, 2025
Insider Transaction Report
Form 4
Derakhshan Behrad
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2025-08-12+5,781→ 26,136 total - Sale
Common Stock
2025-08-12$13.39/sh−2,491$33,360→ 23,645 total - Exercise/Conversion
Restricted Stock Units
2025-08-12−5,781→ 17,344 totalExercise: $0.00Exp: 2034-08-12→ Common Stock (5,781 underlying) - Award
Restricted Stock Units
2025-08-12+30,000→ 30,000 totalExercise: $0.00Exp: 2035-08-12→ Common Stock (30,000 underlying) - Award
Stock Option (Right to Buy)
2025-08-12+180,000→ 180,000 totalExercise: $13.39Exp: 2035-08-12→ Common Stock (180,000 underlying)
Footnotes (5)
- [F1]Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
- [F2]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
- [F4]Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
- [F5]1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.